Dr. Menon will be speaking at the FierceBiotech Dr
Post# of 72440
(Total Views: 217)
Posted On: 09/26/2017 7:49:23 PM
Dr. Menon will be speaking at the FierceBiotech Drug Development Forum tomorrow, September 27.
Add Orphan Indications to Accelerate Development
- Target orphan drug indications to obtain extended periods of exclusivity for blockbuster therapeutics
- Anticipate changes now that politicians and payers expect this
- Weigh the prospect of changes to the orphan drug program, either legislatively or at the FDA regulatory level
http://www.fiercedrugdevforum.com/agenda
FierceBiotech's Drug Development Forum Attracts Executive-Level Biopharma Professionals for Second Annual Conference in Boston This September
BOSTON, June 19, 2017 /PRNewswire/ -- Attendees of FierceBiotech's 2nd Annual Drug Development Forum will obtain essential funding strategies and more productive R&D through executive-level networking opportunities. Convening at the Renaissance Boston Waterfront Hotel September 25–27, 2017, the conference draws together the industry's top decision makers to help guide to success throughout the entire lifecycle — both for products and businesses.
"Our primary objective behind this conference is to build a program for the industry, by the industry and we've been working very closely with our advisory board, our readers, and key industry leaders to develop a program that digs into the real issues facing our industry," said Rebecca Willumson, VP and Publisher of FierceBiotech.
Some sample sessions include:
Meet Increasing Demands for Real-World Evidence
Donald Bergstrom, CMO, MERSANA THERAPEUTICS
Shorten the Path From Preclinical to Clinical Phases
John Hohneker, Executive Vice President, Head of R&D, FORMA THERAPEUTICS Sara Nochur, Senior Vice President, Regulatory Affairs, ALNYLAM PHARMACEUTICALS
Richard Gregory, CSO, IMMUNOGEN
Timothy Lowinger, CSO, MERSANA THERAPEUTICS
Enable Flexibility, Creativity and Independence in Partnerships Between Large and Small Biotech Companies
Michael Bailey, CEO, AVEO ONCOLOGY
Chandra Ramanathan, Vice President and Head, East Coast Innovation Center, BAYER
Cynthia Schwalm, President, North American Commercial Operations, IPSEN
Rich Murray, CEO, JOUNCE THERAPEUTICS
Add Orphan Indications to Accelerate Development
Krishna Menon, CSO, CELLCEUTIX
John Lee, CMO, PHASEBIO PHARMACEUTICALS
How to Succeed in Novel Deal Structures (Even If They're Trying)
Richard Brudnick, Executive Vice President, Business Development, BIOVERATIV Michael Aberman, Vice President, Strategy and Investor Relations, REGENERON Lindsay Rosenwald, CEO, FORTRESS BIOTECH
http://www.prnewswire.com/news-releases/fierc...75241.html
Add Orphan Indications to Accelerate Development
- Target orphan drug indications to obtain extended periods of exclusivity for blockbuster therapeutics
- Anticipate changes now that politicians and payers expect this
- Weigh the prospect of changes to the orphan drug program, either legislatively or at the FDA regulatory level
http://www.fiercedrugdevforum.com/agenda
FierceBiotech's Drug Development Forum Attracts Executive-Level Biopharma Professionals for Second Annual Conference in Boston This September
BOSTON, June 19, 2017 /PRNewswire/ -- Attendees of FierceBiotech's 2nd Annual Drug Development Forum will obtain essential funding strategies and more productive R&D through executive-level networking opportunities. Convening at the Renaissance Boston Waterfront Hotel September 25–27, 2017, the conference draws together the industry's top decision makers to help guide to success throughout the entire lifecycle — both for products and businesses.
"Our primary objective behind this conference is to build a program for the industry, by the industry and we've been working very closely with our advisory board, our readers, and key industry leaders to develop a program that digs into the real issues facing our industry," said Rebecca Willumson, VP and Publisher of FierceBiotech.
Some sample sessions include:
Meet Increasing Demands for Real-World Evidence
Donald Bergstrom, CMO, MERSANA THERAPEUTICS
Shorten the Path From Preclinical to Clinical Phases
John Hohneker, Executive Vice President, Head of R&D, FORMA THERAPEUTICS Sara Nochur, Senior Vice President, Regulatory Affairs, ALNYLAM PHARMACEUTICALS
Richard Gregory, CSO, IMMUNOGEN
Timothy Lowinger, CSO, MERSANA THERAPEUTICS
Enable Flexibility, Creativity and Independence in Partnerships Between Large and Small Biotech Companies
Michael Bailey, CEO, AVEO ONCOLOGY
Chandra Ramanathan, Vice President and Head, East Coast Innovation Center, BAYER
Cynthia Schwalm, President, North American Commercial Operations, IPSEN
Rich Murray, CEO, JOUNCE THERAPEUTICS
Add Orphan Indications to Accelerate Development
Krishna Menon, CSO, CELLCEUTIX
John Lee, CMO, PHASEBIO PHARMACEUTICALS
How to Succeed in Novel Deal Structures (Even If They're Trying)
Richard Brudnick, Executive Vice President, Business Development, BIOVERATIV Michael Aberman, Vice President, Strategy and Investor Relations, REGENERON Lindsay Rosenwald, CEO, FORTRESS BIOTECH
http://www.prnewswire.com/news-releases/fierc...75241.html
(5)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼